Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges: 2023-2025

Historic Amortization of Deferred Charges for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to $638,000.

  • Inhibrx Biosciences' Amortization of Deferred Charges was N/A to $638,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 57.85% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Amortization of Deferred Charges stood at $638,000 for Q3 2025, which was up 1.92% from $626,000 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Amortization of Deferred Charges ranged from a high of $1.2 million in Q4 2023 and a low of $533,000 during Q1 2025.
  • Over the past 3 years, Inhibrx Biosciences' median Amortization of Deferred Charges value was $823,000 (recorded in 2024), while the average stood at $906,857.
  • Data for Inhibrx Biosciences' Amortization of Deferred Charges shows a maximum YoY plummeted of 57.09% (in 2025) over the last 5 years.
  • Over the past 3 years, Inhibrx Biosciences' Amortization of Deferred Charges (Quarterly) stood at $1.2 million in 2023, then reached $823,000 in 2024, then decreased by 23.94% to $638,000 in 2025.
  • Its Amortization of Deferred Charges stands at $638,000 for Q3 2025, versus $626,000 for Q2 2025 and $533,000 for Q1 2025.